MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Pliant Therapeutics Inc

Fechado

1.25 4.17

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.17

Máximo

1.26

Indicadores-chave

By Trading Economics

Rendimento

-6.4M

-56M

EPS

-0.92

Funcionários

171

EBITDA

-10M

-59M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+583.76% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-21M

77M

Abertura anterior

-2.92

Fecho anterior

1.25

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jul. de 2025, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jul. de 2025, 23:15 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 de jul. de 2025, 22:59 UTC

Conversa de Mercado

Uranium Market About to Enter Lull -- Market Talk

3 de jul. de 2025, 22:58 UTC

Conversa de Mercado

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 de jul. de 2025, 22:47 UTC

Conversa de Mercado

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 de jul. de 2025, 22:21 UTC

Ganhos

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

3 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

3 de jul. de 2025, 20:41 UTC

Conversa de Mercado

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 de jul. de 2025, 20:41 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de jul. de 2025, 19:28 UTC

Conversa de Mercado

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 de jul. de 2025, 19:03 UTC

Conversa de Mercado

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 de jul. de 2025, 18:34 UTC

Conversa de Mercado

Gold Has Winning Week, But Down Day -- Market Talk

3 de jul. de 2025, 18:18 UTC

Conversa de Mercado

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 de jul. de 2025, 18:06 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de jul. de 2025, 18:06 UTC

Conversa de Mercado

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 de jul. de 2025, 17:27 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 de jul. de 2025, 16:55 UTC

Ganhos

Travel Stocks Could Offer Investors a Glorious -2-

3 de jul. de 2025, 16:55 UTC

Ganhos

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Correction to Health Care Roundup: Market Talk

3 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jul. de 2025, 16:05 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jul. de 2025, 16:05 UTC

Conversa de Mercado

Gold Futures Fall Following Jobs Report -- Market Talk

3 de jul. de 2025, 15:47 UTC

Ganhos

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 de jul. de 2025, 15:36 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

583.76% parte superior

Previsão para 12 meses

Média 8 USD  583.76%

Máximo 17 USD

Mínimo 3 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

1

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.43 / 1.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.